NRSN
Neurosense Therapeutics Ltd
NASDAQ: NRSN · HEALTHCARE · BIOTECHNOLOGY
$0.80
-0.72% today
Updated 2026-04-29
Market cap
$26.53M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.44
Dividend yield
—
52W range
$1 – $3
Volume
0.2M
Neurosense Therapeutics Ltd (NRSN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | $955000.00 | $779000.00 | $11.43M | $7.71M | $3.18M | $4.58M |
| Cash & equivalents | $895000.00 | $699000.00 | $11.06M | $3.54M | $2.64M | $3.38M |
| Current assets | $913000.00 | $729000.00 | $11.41M | $7.38M | $2.92M | $4.40M |
| Total liabilities | $37000.00 | $120000.00 | $2.42M | $2.09M | $4.94M | $1.99M |
| Current liabilities | $37000.00 | $120000.00 | $597000.00 | $1.73M | $3.46M | $1.99M |
| Long-term debt | — | — | — | — | — | — |
| Shareholder equity | $918000.00 | $659000.00 | $9.01M | $5.62M | $-1.87M | $2.58M |
| Retained earnings | $-1.58M | $-4.41M | $-8.45M | $-20.79M | $-26.12M | $-36.66M |
| Accounts receivable | $18000.00 | $30000.00 | $178000.00 | $131000.00 | $166000.00 | $164000.00 |
| Inventory | $-18.00 | $-67.00 | $-178000.00 | $-3.68M | — | — |
| Goodwill | — | — | — | — | — | — |